Mdr1b
-/-, Abcg2 -/-) mice (TKO-mice) and Cyp3a-/-knockout mice (Cyp-mice).
28
WT-mice and Cyp-mice were pre-treated with a P-gp/Bcrp inhibitor elacridar (5 mg/kg) 29 and the HIV-protease inhibitor and boosting agent, ritonavir (2 mg/kg I.V.), respectively.
30
Atazanavir (10 mg/kg) was administered I.V. Plasma (C plasma ), brain (C brain ) and testes (C testes ) 31 atazanavir concentrations were quantified at various times by LC-MS/MS. 32 In TKO-mice, we demonstrated a significant increase in atazanavir C brain :C plasma (5.4 -fold) 33 and C testes :C plasma (4.6-fold) ratios compared to WT-mice (p<0.05). Elacridar-treated WT-mice 34 showed a significant increase in atazanavir C brain :C plasma (12. 3-fold) and C testes :C plasma (13.5-fold) 35 ratios compared to vehicle-treated WT-mice, respectively. In Cyp-mice pre-treated with 36 ritonavir, significant (p<0.05) increases in atazanavir C brain :C plasma (1.8-fold) and C testes :C plasma (9.5-37 fold) ratios compared to vehicle-treated WT-mice were observed. 38 These data suggest that drug efflux transporters i.e., P-gp, are involved in limiting 39 atazanavir permeability in rodent brain and genital tract. Since these transporters are known to 40
Introduction

44
The use of human immunodeficiency virus (HIV) protease inhibitors for the treatment of 45 HIV infection remains a primary and effective component of combination antiretroviral therapy 46 (1,2). Patients on antiretroviral therapy must maintain a high level of adherence in order to 47 suppress viral replication and reduce the opportunity for HIV to develop drug resistance (3).
48
Although the current use of combination antiretroviral therapy is capable of suppressing HIV 49 replication in plasma, it is unable to completely eradicate the virus from the host (4) . One of the 50 challenges to achieve total HIV eradication is the existence of viral sanctuaries such as the brain 51 and the male genital tract that are protected by the blood-brain barrier (BBB) (5) and blood-52 testis barrier (BTB), respectively (6). These sanctuaries sites allow HIV to evade eradication even 53 if effective antiretroviral drug concentrations are achieved in plasma (7), and could contribute 54 to the development of HIV-associated neurocognitive disorders (8), increased risk of viral 55 shedding into seminal fluid of HIV infected men (9), and ultimately, serve as a potential source 56 for systemic viral repopulation if a patient interrupts drug therapy (7).
57
The BBB constitutes a physical and biochemical barrier between the brain parenchyma 58 and systemic circulation and is primarily composed of brain microvessel endothelial cells that 59 form tight cell-cell junctions which significantly restricts paracellular permeability of xenobiotics 60 into and out of the brain (10 
Quantification of Tissue and Plasma Atazanavir Concentrations by LC-MS/MS
226
Chromatographic separation was carried out at 40°C with a gradient mobile phase run.
227
The mobile phase consisted of mobile phase A (0.1% acetic acid in water) and mobile phase B (Table 2) .
Results
266
ABC Transporter Protein Expression in Brain and Testes of WT-and TKO-mice
287
Pharmacokinetic parameters of atazanavir in WT-and TKO-mice plasma 288 We determined the concentration of atazanavir in plasma (C plasma ) in WT-and TKO-mice ). We did not observe any significant changes in the rate constants k 21 , which represents the 299 rate at which atazanavir leaves the tissue compartment into plasma, or k 10 , which represents 300 the rate of elimination of atazanavir from the plasma compartment (Table 3) .
301
Atazanavir Brain and Testes Concentrations in WT-mice and TKO-mice
302
We examined the concentration of atazanavir in brain (C brain ) ( Figure 2A ) and testes 
